The global heterozygous familial hypercholesterolemia (HEFH) market is on track for significant growth, projected to reach a staggering US$58.54 billion by 2033. This represents a remarkable increase from an estimated US$15.11 billion in fiscal year 2023, reflecting a robust compound annual growth rate (CAGR) of 14.5%.
HEFH is an inherited condition characterized by high levels of low-density lipoprotein (LDL) cholesterol, also known as “bad cholesterol.” This buildup of cholesterol can restrict blood flow and significantly increase the risk of heart attack and stroke.
One of the main reasons influencing the growth of such a kind of hypercholesterolemia market’s revenue is the rise in the frequency of hypercholesterolemia brought on by an increase in the number of people living unhealthy lifestyles, which causes obesity. The aging population, the prevalence of cardiovascular disease, and several other chronic conditions including diabetes, renal troubles, and thyroid issues all enhance the risk of hypercholesterolemia, which boosts the market’s revenue in turn. The introduction of new drugs, increased research, and technological developments in the Management of hypercholesterolemia all contribute to the market’s revenue expansion.
Get Latest Sample Copy:
https://www.futuremarketinsights.com/reports/sample/rep-gb-16343
However, the high cost of existing Managements, a variety of risk concerns related to the medications used to treat hypercholesterolemia, and a lack of diagnostic tools for the condition are the main issues limiting the market’s ability to grow in terms of revenue. Various government initiatives to raise awareness about the symptoms, cause, and available Managements for hypercholesterolemia, technological developments in the Management of hypercholesterolemia, enhanced healthcare facilities, rising research and drug development for the Management, and higher healthcare investments are expected to create profitable growth opportunities during the forecast period. Such developments are expected to spur growth.
Key Takeaways from the Market Study
- The global HEFH management market is currently worth more than US$ 13 Billion.
- In 2023, the ST-103 segment by product type is expected to take the dominant market share of 32%.
- Hospitals to account for over 1/5th of all HEFH management procedures as of 2023
- North America is expected to exhibit CAGR of 15.3% from 2023-2033, with regard to HEFH management
- The European market for HEFH management is expected to grow with a steady CAGR of 14% from 2023-2033
“The improvement of healthcare infrastructure, government initiatives to raise public awareness of the causes, symptoms, and treatments for hypercholesterolemia, improved research and drug development for the treatment, as well as increased healthcare investments will all contribute to the growth of the heterozygous familial hypercholesterolemia management market during the forecast period.” comments a Future Market Insights analyst.
Explore Our Proven Research Methodology:
https://www.futuremarketinsights.com/request-report-methodology/rep-gb-16343
Competitive Landscape
Some of the top players in the global market are Sanofi SA, Amgen Inc., Novartis International AG, AdooQ Bioscience, Thermo Fisher Scientific, Universal Biologicals, Selleck Chemicals, Madrigal Pharmaceuticals, ShangHai Caerulum Pharma Discovery Co., Ltd. and Wuhan Biocar Pharmacy. Some recent developments in this domain are:
- NewAmsterdam Pharma, a clinical-stage business focusing on the discovery and development of transformational oral treatments for metabolic illnesses, said today that it has begun a Phase 2 dose-finding trial of obicetrapib as an addition to stable statin therapy among Japanese patients with dyslipidemia with BROOKLYN in 2022. In addition to maximally tolerated lipid-lowering treatment, the BROOKLYN Phase 3 study examines the impact of obicetrapib on LDL-C levels in individuals with heterozygous familial hypercholesterolemia.
More Valuable Insights Available
Future Market Insights, in its new offering, presents an unbiased analysis of the Heterozygous Familial Hypercholesterolemia (HEFH) Management Market, presenting historical demand data (2018-2022) and forecast statistics from 2023 to 2033.
The study divulges essential insights on the market based on the Heterozygous Familial Hypercholesterolemia (HEFH) Management Market by product type (Gemcabene Calcium, MGL-3196, ST-103, Others), by application (hospitals, medical centers and clinics) and regions.
About the Healthcare Division at Future Market Insights
The healthcare team at Future Market Insights offers expert analysis, time efficient research, and strategic recommendations with an objective to provide authentic insights and accurate results to help clients worldwide. With a repertoire of over 100+ reports and 1 million+ data points, the team has been analyzing the industry lucidly in 50+ countries for over a decade. The team provides a brief analysis on key trends including competitive landscape, profit margin, and research development efforts.
Key Segments Covered in the Heterozygous Familial Hypercholesterolemia (HEFH) Management Market Report
By Product Type:
- Gemcabene Calcium
- MGL-3196
- ST-103
- Others
By Application:
- Hospitals
- Medical Centers
- Clinics
- Others
Explore In-Depth Market Research: Purchase Now to Access:
https://www.futuremarketinsights.com/checkout/16343
About Future Market Insights (FMI)
Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 400 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.
Contact Us:
Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube
